Procedureless Gastric Balloon Encourages Weight Loss
By HospiMedica International staff writers Posted on 23 Dec 2015 |
Image: The Elipse procedureless gastric balloon (Photo courtesy of Allurion Technologies).S
An innovative gastric balloon offers an alternative treatment option for overweight and obese individuals.
The Elipse procedureless gastric balloon is a thin, flexible polymer film balloon that is delivered in a swallowable capsule, thus eliminating the need for surgery, endoscopy, or anesthesia. Once in position, it is filled with liquid through a thin delivery catheter, which is then detached by tugging. The gastric balloon remains in the stomach for four months, after which it automatically empties and is excreted naturally from the body. The Elipse will be offered by physicians in conjunction with a medically supervised diet and exercise program.
The Elipse has undergone clinical studies in people with a body mass index (BMI) of 27-40 kg/m2. Study findings indicated an average weight loss of 10 kilograms, with participants losing 37% of their excess weight and eight centimeters off their waist circumference over the four month treatment period. Participants also saw improvements in triglyceride and hemoglobin HbA1c levels, and all balloons were safely and naturally excreted. The Elipse procedureless gastric balloon is a product of Allurion Technologies (Wellesley, MA, USA), and has received the European Community CE marking of approval.
“Excess weight often has a profound impact on health and quality of life, including work, relationships, and self-perception. But of nearly two billion overweight and obese adults worldwide, less than one percent have embraced currently available surgical and endoscopic options,” said Shantanu Gaur, MD, co-founder and chief scientific officer of Allurion Technologies. “Weight loss therapies that require surgery, endoscopy, or anesthesia are often too invasive and can be too expensive for people who might otherwise greatly benefit from them.”
“Following six years of development, we are very excited to enter the next phase of our company's growth,” said Jonathan Wecker, CEO of Allurion Technologies. “I am extremely proud of our team and thankful for the support of the many physicians and allied caregivers that have helped make Elipse a reality.”
Related Links:
Allurion Technologies
The Elipse procedureless gastric balloon is a thin, flexible polymer film balloon that is delivered in a swallowable capsule, thus eliminating the need for surgery, endoscopy, or anesthesia. Once in position, it is filled with liquid through a thin delivery catheter, which is then detached by tugging. The gastric balloon remains in the stomach for four months, after which it automatically empties and is excreted naturally from the body. The Elipse will be offered by physicians in conjunction with a medically supervised diet and exercise program.
The Elipse has undergone clinical studies in people with a body mass index (BMI) of 27-40 kg/m2. Study findings indicated an average weight loss of 10 kilograms, with participants losing 37% of their excess weight and eight centimeters off their waist circumference over the four month treatment period. Participants also saw improvements in triglyceride and hemoglobin HbA1c levels, and all balloons were safely and naturally excreted. The Elipse procedureless gastric balloon is a product of Allurion Technologies (Wellesley, MA, USA), and has received the European Community CE marking of approval.
“Excess weight often has a profound impact on health and quality of life, including work, relationships, and self-perception. But of nearly two billion overweight and obese adults worldwide, less than one percent have embraced currently available surgical and endoscopic options,” said Shantanu Gaur, MD, co-founder and chief scientific officer of Allurion Technologies. “Weight loss therapies that require surgery, endoscopy, or anesthesia are often too invasive and can be too expensive for people who might otherwise greatly benefit from them.”
“Following six years of development, we are very excited to enter the next phase of our company's growth,” said Jonathan Wecker, CEO of Allurion Technologies. “I am extremely proud of our team and thankful for the support of the many physicians and allied caregivers that have helped make Elipse a reality.”
Related Links:
Allurion Technologies
Latest Surgical Techniques News
- Miniaturized Implantable Multi-Sensors Device to Monitor Vessels Health
- Tiny Robots Made Out Of Carbon Could Conduct Colonoscopy, Pelvic Exam or Blood Test
- Miniaturized Ultrasonic Scalpel Enables Faster and Safer Robotic-Assisted Surgery
- AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy Detects More Lesions
- First-Ever Contact Force Pulsed Field Ablation System to Transform Treatment of Ventricular Arrhythmias
- Caterpillar Robot with Built-In Steering System Crawls Easily Through Loops and Bends
- Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries
- Small, Implantable Cardiac Pump to Help Children Awaiting Heart Transplant
- Gastrointestinal Imaging Capsule a Game-Changer in Esophagus Surveillance and Treatment
- World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets
- Artificial Intelligence Broadens Diagnostic Abilities of Conventional Coronary Angiography
- AI-Powered Surgical Visualization Tool Supports Surgeons' Visual Recognition in Real Time
- Cutting-Edge Robotic Bronchial Endoscopic System Provides Prompt Intervention during Emergencies
- Handheld Device for Fluorescence-Guided Surgery a Game Changer for Removal of High-Grade Glioma Brain Tumors
- Porous Gel Sponge Facilitates Rapid Hemostasis and Wound Healing
- Novel Rigid Endoscope System Enables Deep Tissue Imaging During Surgery